Supernus Pharmaceuticals (NASDAQ:SUPN)

CAPS Rating: 2 out of 5

Results 1 - 8 of 8

Recs

0
Member Avatar OklaBoston (59.90) Submitted: 4/27/2015 3:20:42 PM : Outperform Start Price: $12.96 SUPN Score: +2.70

Long term technicals look stronger than short term ones.

Solid Q/Q numbers.

Recs

0
Member Avatar camarodan64 (95.91) Submitted: 3/13/2015 12:50:35 PM : Outperform Start Price: $11.54 SUPN Score: +12.77

drugs and profits here, at 11.40 is a buy i see $30 this year

Recs

0
Member Avatar mirqce (< 20) Submitted: 11/21/2014 7:24:48 PM : Outperform Start Price: $8.94 SUPN Score: +47.53

two new drugs two more in pipe line low debt some cash good management

Recs

0
Member Avatar manirg (87.67) Submitted: 8/13/2014 4:22:36 PM : Outperform Start Price: $9.03 SUPN Score: +40.45

low valuation

Recs

0
Member Avatar cavemantrader (84.12) Submitted: 12/24/2013 10:58:05 AM : Outperform Start Price: $8.69 SUPN Score: +38.10

The FDA approved United Therapeutics' drug Orenitram Friday evening. The drug is intended to treat pulmonary arterial hypertension. This could bring SUPN at least 250 million going forward, yet the stock barely moved to the upside. It appears a large number of funds were not expecting the extremely positive development and were shorting the stock, but after some fund manipulation to cover and mitigate losses, expect shares to breakout to the double digits in the near term.

Recs

0
Member Avatar ptanabe (75.78) Submitted: 7/31/2013 6:46:48 PM : Outperform Start Price: $6.87 SUPN Score: +70.34

k

Recs

0
Member Avatar 21Emoney21 (< 20) Submitted: 10/19/2012 2:27:45 PM : Outperform Start Price: $13.03 SUPN Score: -45.54

Expect to see FDA approval today on new drug

Recs

0
Member Avatar SamsaricSufferer (49.38) Submitted: 7/4/2012 8:35:17 PM : Outperform Start Price: $9.69 SUPN Score: -16.88

PDUFA coming up

Results 1 - 8 of 8

Featured Broker Partners


Advertisement